Haleon (HLN) Cash from Investing Activities (2021 - 2023)
Haleon (HLN) posted Cash from Investing Activities of -$233.3 million for Q4 2023, up 97.68% on a QoQ basis from -$10.1 billion in Q4 2022, and up 97.68% year-over-year from -$118.0 million in Q4 2022.
Haleon (HLN) Cash from Investing Activities (2021 - 2023) Analysis & Trends
Haleon's Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$233.3 million for Q4 2023.
- Quarterly Cash from Investing Activities rose 97.68% year-over-year to -$233.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$20.3 billion (changed N/A YoY) and the FY2025 annual result came in at -$456.2 million, down 167.59% from the prior year.
- Cash from Investing Activities was -$233.3 million for Q4 2023 at Haleon, up from -$10.1 billion in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $624.1 million in Q4 2021 and bottomed at -$10.6 billion in Q3 2022.
- A 3-year average of -$5.1 billion and a median of -$5.2 billion in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 1713.76% — and 2023, when it jumped 97.68%.
- Haleon's Cash from Investing Activities stood at $624.1 million in 2021, then sank by 1713.76% to -$10.1 billion in 2022, then soared by 97.68% to -$233.3 million in 2023.
- Business Quant data shows HLN's Cash from Investing Activities at -$233.3 million in Q4 2023, -$10.1 billion in Q4 2022, and -$10.6 billion in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.02 Bn | 32.28 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.94 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.35 Bn | 18.54 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -233.34 Mn |
| Dec 31, 2023 | -233.34 Mn |
| Dec 31, 2022 | -10.07 Bn |
| Dec 31, 2022 | -10.07 Bn |
| Sep 20, 2022 | -10.57 Bn |
| Sep 20, 2022 | -10.57 Bn |
| Dec 31, 2021 | 624.13 Mn |
| Dec 31, 2021 | 624.13 Mn |